Nilotinib
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Using the evidence pack provided, here is the drug repurposing evaluation report.
Nilotinib: From Chronic Myeloid Leukemia to Dermatofibrosarcoma Protuberans
One-Sentence Summary
Nilotinib is a second-generation tyrosine kinase inhibitor originally developed for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), but this direction is currently supported by only 0 clinical trials and 1 publication, meaning the evidence base is mechanistic rather than clinical at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic Myeloid Leukemia (Ph+ CML)† |
| Predicted New Indication | Dermatofibrosarcoma Protuberans |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L4 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
† Not present in the evidence pack's original_indications/original_moa fields (flagged as a data gap, DG002). This is based on generally known information about nilotinib rather than the supplied evidence pack.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack (data gap DG002). Based on generally known information, nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor (TKI) whose efficacy in Ph+ chronic myeloid leukemia is well established; it also has recognized off-target inhibitory activity against PDGFR-α/β and KIT.
Dermatofibrosarcoma protuberans (DFSP) is a soft-tissue sarcoma characteristically driven by a COL1A1-PDGFB gene fusion, which causes constitutive activation of the PDGFR-β signaling pathway. Imatinib, a first-generation TKI in the same pharmacological class as nilotinib, is already an established treatment for unresectable or metastatic DFSP precisely because of its anti-PDGFR activity. This creates a plausible mechanistic bridge between nilotinib's known target profile and DFSP biology.
The single retrieved literature item (PMID 29408302) reviews the broader role of small-molecule PDGFR inhibitors — as a class — in neoplastic disease, which is consistent with this rationale but does not provide nilotinib-specific or DFSP-specific clinical outcome data. The prediction should therefore be regarded as mechanistically plausible but not yet clinically validated.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29408302 | 2018 | Review | Pharmacological Research | Reviews the role of small-molecule PDGFR inhibitors (a class that includes nilotinib) in treating neoplastic disorders; supports a mechanistic, but not DFSP-specific, rationale for PDGFR-driven tumors |
Norway Market Information
Nilotinib is currently not marketed in Norway — no marketing authorizations are recorded in the evidence pack.
Cytotoxicity
Nilotinib is an antineoplastic agent (original indication is a hematologic malignancy, CML), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BCR-ABL/PDGFR/KIT tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The TxGNN score is high, but the underlying evidence base is limited to a single mechanism-class review article with no DFSP-specific or nilotinib-specific clinical data, and zero registered clinical trials — placing this at Evidence Level L4 (mechanism-only).
- Critical safety information (TFDA/product label warnings and contraindications) is marked as a Blocking data gap (DG001), which by definition prevents this candidate from entering the S1 safety preliminary evaluation stage.
To proceed, the following is needed:
- TFDA package insert data (warnings, contraindications) — currently blocking, must be resolved first
- Confirmed mechanism of action (MOA) detail from DrugBank (data gap DG002)
- Disease-specific evidence for nilotinib in DFSP, particularly in imatinib-resistant or PDGFB-rearranged cases
- Drug-drug interaction (DDI) profile, currently unresolved (
not_found) - Confirmation of Norway marketing/import pathway, given the drug is not currently marketed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.